---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-040007"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:56:52.952027+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q2 net loss $4.7M, cash $38.3M; receives Nasdaq extension to Feb 2026

## Summary
- Net loss of $4.7M ($0.06 EPS) vs net income of $8.5M ($0.12 EPS) in Q2 2024.
- Revenue from royalty agreements $6.3M (vs $169K), including $7.0M ganaxolone royalty monetization with Immedica.
- Cash $38.3M, expected to fund operations into early 2H 2026.
- OV329 Phase 1 topline safety/biomarker results anticipated Q3 2025.
- Company transferred to Nasdaq Capital Market with extended bid price compliance deadline to Feb 9, 2026.

## SEC filing metadata
- accession: 0001628280-25-040007
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828025040007/0001628280-25-040007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828025040007/ovid-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-040007
- JSON: https://secwatch.observer/filing/0001628280-25-040007.json
- Plain text: https://secwatch.observer/filing/0001628280-25-040007.txt

## Key facts
- Listing & Compliance Notices
  Ovid Therapeutics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: August 12, 2025, that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until February 9, 2026 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on August 14, 2025, the Company’s common stock will be transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “OVID.” The Company intends to monitor the closing bid
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828025040007/0001628280-25-040007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.